Guided Therapeutics (GTHP) 10-K 25 Mar 15 2014 FY Annual report Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2014	Mar. 16, 2015	Jun. 30, 2014
Document And Entity Information
Entity Registrant Name	GUIDED THERAPEUTICS INC
Entity Central Index Key	924515
Document Type	10-K
Document Period End Date	31-Dec-14
Amendment Flag	FALSE
Current Fiscal Year End Date	-19
Is Entity a Well-known Seasoned Issuer?	No
Is Entity a Voluntary Filer?	No
Is Entity's Reporting Status Current?	Yes
Entity Filer Category	Smaller Reporting Company
Entity Public Float			$36,615,302
Entity Common Stock, Shares Outstanding		97,184,341
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2014

CONDENSED_CONSOLIDATED_BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
ASSETS
Cash and cash equivalents	$162	$613
Accounts receivable, net of allowance for doubtful accounts of $76 and $18 at December 31, 2014 and 2013, respectively	338	133
Inventory, net of reserves of $144 and $184 at December 31, 2014 and 2013, respectively	1,180	1,193
Other current assets	99	101
Total current assets	1,779	2,040
Property and equipment, net	587	920
Other assets	101	356
Debt Issue Cost	564	0
Total noncurrent assets	1,252	1,276
TOTAL ASSETS	3,031	3,316
LIABILITIES AND STOCKHOLDERS' EQUITY
Short-term notes payable	646	35
Current portion of long-term debt	123	109
Short-term notes payable, net of discount	1,062	0
Accounts payable	1,733	891
Accrued liabilities	1,015	723
Deferred revenue	24	14
Total current liabilities	4,603	1,772
Warrants, at fair value	2,070	1,548
Long-term debt, net	40	103
Convertible note, net of discount	783	0
Total long-term liabilities	2,893	1,651
TOTAL LIABILITIES	7,496	3,423
STOCKHOLDERS' EQUITY :
Series B convertible preferred stock, $.001 par value; 3 shares authorized, 1.2 and 2.1 shares issued and outstanding as of December 31, 2014 and 2013, respectively (liquidation preference of $1,200 and $2,100 at December 31, 2014 and 2013, respectively)	678	1,139
Common stock, $.001 par value; 195,000 and 145,000 shares authorized, 96,889 and 70,479 shares issued and outstanding as of December 31, 2014 and 2013, respectively	97	71
Additional paid-in capital	107,952	101,840
Treasury stock, at cost	-132	-132
Accumulated deficit	-113,060	-103,025
TOTAL GUIDED THERAPEUTICS STOCKHOLDERS' EQUITY	-4,465	-107
TOTAL STOCKHOLDERS’ (DEFICIT) EQUITY	-4,465	-107
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$3,031	$3,316

CONDENSED_CONSOLIDATED_BALANCE1

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, except Share data, unless otherwise specified
CURRENT ASSETS
Accounts receivable, net of allowance	$76	$18
Inventory, net of reserves	$144	$184
STOCKHOLDERS' EQUITY :
Series B convertible preferred stock, par value	$0.00	$0.00
Series B convertible preferred stock, authorized	3	3
Series B convertible preferred stock, issued	1.2	2.1
Series B convertible preferred stock, outstanding	1.2	2.1
Common stock, par value	$0.00	$0.00
Common stock, Authorized	195,000	145,000
Common stock, Issued	96,889	70,479
Common stock, outstanding	96,889	70,479

CONDENSED_CONSOLIDATED_STATEME

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
REVENUE:
Sales - devices and disposables	$758	$359
Cost of goods sold	891	611
Gross Loss	-133	-252
Contract and grant revenue	65	820
OPERATING EXPENSES:
Research and development	2,788	2,742
Sales and marketing	1,164	901
General and administrative	4,649	3,533
Total operating expenses	8,601	7,174
Operating loss	-8,669	-6,606
Other income	25	110
Interest expense	-979	-45
Loss on extinguishment of debt	-325	0
Change in fair value of warrants	65	-674
Total other income	-1,214	-609
LOSS  FROM OPERATIONS	-9,883	-7,215
PROVISION FOR INCOME TAXES	0	0
NET LOSS	-9,883	-7,215
DEEMED DIVIDENDS	0	-3,175
PREFERRED STOCK DIVIDENDS	-152	0
NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS	($10,035)	($10,390)
BASIC AND DILUTED NET LOSS PER SHARE ATTRIBUTABLE TO COMMON STOCKHOLDERS	($0.13)	($0.16)
WEIGHTED AVERAGE SHARES OUTSTANDING	77,061	65,884

CONSOLIDATED_STATEMENTS_OF_CHA

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS EQUITY (USD $)	Preferred Stock Series B	Common Stock	Additional Paid-In Capital	Treasury Stock	Accumulated Deficit	Total
In Thousands, except Share data
Beginning Balance, Amount at Dec. 31, 2012	$0	$62	$93,273	($104)	($92,098)	$1,133
Beginning Balance, Shares at Dec. 31, 2012	0	62,282
Issuance of Series B preferred stock, Amount	1,341
Issuance of Series B preferred stock, Shares	3
Deemed dividends on beneficial conversion feature of preferred stock			-3,148			-3,148
Preferred dividends					-27
Conversion of preferred stock, Amount	-202	1	201
Conversion of preferred stock, Shares	-1	878
Issuance of common stock, Amount		1	462			162
Issuance of common stock, Shares		670
Issuance of stock options			126
Exercise of warrants/options, Amount		7	3,269			3,102
Exercise of warrants/options, Shares		6,649
Stock-based compensation expense			824			824
Deemed dividends			537		-537
Acquisition of treasury stock				-28
Net Loss					-7,215	-7,215
Ending Balance, Amount at Dec. 31, 2013	1,139	71	101,840	-132	-103,025	-107
Ending Balance, Shares at Dec. 31, 2013	2	70,479
Conversion of preferred stock, Amount	-461	2	459
Conversion of preferred stock, Shares	-1	2,311
Issuance of common stock and warrants, Amount		21	3,348			3,369
Issuance of common stock and warrants, Shares		20,872
Issuance of warrants			372			372
Issuance of stock options			61			61
Exercise of warrants/options, Amount		96				96
Exercise of warrants/options, Shares	441
Stock-based compensation expense			886			886
Stock-based compensation expense, Shares		2
Conversion of debts into common stock, Amount		3	890			893
Conversion of debts into common stock, Shares		2,784
Net Loss					-9,883	-9,883
Ending Balance, Amount at Dec. 31, 2014	$678	$97	$107,952	($132)	($113,060)	($4,465)
Ending Balance, Shares at Dec. 31, 2014	1	96,889

CONDENSED_CONSOLIDATED_STATEME1

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	($9,883)	($7,215)
Adjustments to reconcile net loss to net cash used in operating activities
Bad debt expense	63	7
Loss on extinguishment of debt	325	0
Depreciation	483	461
Amortization	757	0
Stock based compensation	886	824
Change in fair value of warrants	-65	674
Changes in operating assets and liabilities:
Accounts receivable	-267	-33
Inventory	14	-669
Other current assets	2	97
Other assets	254	-25
Accounts payable	842	126
Deferred revenue	10	-26
Accrued liabilities	296	223
Total adjustments	3,600	1,659
Net cash used in operating activities	-6,283	-5,556
CASH FLOWS FROM INVESTING ACTIVITIES:
Additions to fixed assets	-150	-107
Net cash used in investing activities	-150	-107
CASH FLOWS FROM FINANCING ACTIVITIES:
Net proceeds from issuance of common stock and warrants, net	1,730	2,214
Proceeds from debt financing, net of discount	5,263	115
Loan acquisition costs	-452	0
Payments on notes payables	-656	-374
Proceeds from options and warrants exercised	97	3,276
Net cash provided by financing activities	5,982	5,231
NET CHANGE IN CASH AND CASH EQUIVALENTS	-451	-432
CASH AND CASH EQUIVALENTS, beginning of year	613	1,045
CASH AND CASH EQUIVALENTS, end of year	162	613
SUPPLEMENTAL SCHEDULE OF:
Cash paid for Interest	33	31
NONCASH INVESTING AND FINANCING ACTIVITIES:
Conversion of accrued expenses into common stock	207	126
Payment of debt issuance costs via warrants and common stock	522	0
Conversion of convertible debt into common stock	893	0
Repayment of debt via issuance of common stock and warrants	1,697	0
Issuance of common stock as board compensation	355	463
Deemed dividends in the form of warrants to purchase common stock.	0	537
Deemed dividends on preferred stock	$0	$3,148

1_Organization_Background_and_

1. Organization, Background, and Basis of Presentation	12 Months Ended
	Dec. 31, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]
1. Organization, Background, and Basis of Presentation	Guided Therapeutics, Inc. (formerly SpectRx, Inc.), together with its wholly owned subsidiary, InterScan, Inc. (formerly Guided Therapeutics, Inc.), collectively referred to herein as the “Company”, is a medical technology company focused on developing innovative medical devices that have the potential to improve healthcare. The Company’s primary focus is the commercialization of its LuViva™ non-invasive cervical cancer detection device and extension of its cancer detection technology into other cancers, including esophageal. The Company’s technology, including products in research and development, primarily relates to biophotonics technology for the non-invasive detection of cancers.
	Basis of Presentation
	All information and footnote disclosures included in the consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States.
	The Company’s prospects must be considered in light of the substantial risks, expenses and difficulties encountered by entrants into the medical device industry. This industry is characterized by an increasing number of participants, intense competition and a high failure rate. The Company has experienced net losses since its inception and, as of December 31, 2014, it had an accumulated deficit of approximately $113.1 million. Through December 31, 2014, the Company has devoted substantial resources to research and development efforts. The Company first generated revenue from product sales in 1998, but does not have significant experience in manufacturing, marketing or selling its products. The Company’s development efforts may not result in commercially viable products and it may not be successful in growing sales for its products. Moreover, required regulatory clearances or approvals may not be obtained. The Company’s products may not ever gain market acceptance and the Company may not ever achieve levels of revenue to sustain further development costs and support ongoing operations or achieve profitability. The development and commercialization of the Company’s products will require substantial development, regulatory, sales and marketing, manufacturing and other expenditures. The Company expects operating losses to continue through the foreseeable future as it continues to expend substantial resources to complete development of its products, obtain regulatory clearances or approvals and conduct further research and development.
	Going Concern
	The Company’s consolidated financial statements have been prepared and presented on a basis assuming it will continue as a going concern.  The factors below raise substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might be necessary from the outcome of this uncertainty. Notwithstanding the foregoing, the Company believes it has made progress in recent years in stabilizing its financial situation by execution of multiyear contracts from Konica Minolta Opto, Inc., a subsidiary of Konica Minolta, Inc., a Japanese corporation based in Tokyo (“Konica Minolta”) and grants from the National Cancer Institute (“NCI”), while at the same time simplifying its capital structure and significantly reducing debt. However, the Company has replaced its prior agreements with Konica Minolta with a new licensing agreement, and therefore will no longer receive direct payments from Konica Minolta, and will have to pay a royalty to Konica Minolta should the Company sell any products licensed from Konica Minolta.
	At December 31, 2014, the Company had a negative working capital of approximately $2.8 million, accumulated deficit of $113.1 million, and incurred a net loss of $9.9 million for the year then ended. Stockholders’ deficit totaled approximately $4.5 million at December 31, 2014, primarily due to recurring net losses from operations, deemed dividends on warrants and preferred stock, offset by proceeds from the exercise of options and warrants and proceeds from sales of stock.
	The Company’s capital-raising efforts are ongoing. If sufficient capital cannot be raised during the second quarter of 2015, the Company has plans to curtail operations by reducing discretionary spending and staffing levels, and attempting to operate by only pursuing activities for which it has external financial support and additional NCI, NHI or other grant funding. However, there can be no assurance that such external financial support will be sufficient to maintain even limited operations or that the Company will be able to raise additional funds on acceptable terms, or at all. In such a case, the Company might be required to enter into unfavorable agreements or, if that is not possible, be unable to continue operations, and to the extent practicable, liquidate and/or file for bankruptcy protection.
	The Company had warrants exercisable for approximately 29.8 million shares of its common stock outstanding at December 31, 2014, with exercise prices of $0.15 to $1.08 per share. Exercises of these warrants would generate a total of approximately $10.1 million in cash, assuming full exercise, although the Company cannot be assured that holders will exercise any warrants. Management may obtain additional funds through the private sale of preferred stock or debt securities, public and private sales of common stock, and grants, if available.
	Assuming the Company receives FDA approval for its LuViva cervical cancer detection device in 2015, the Company currently anticipates an early 2016 product launch in the United States. Product launch outside the United States began in the second half of 2013.

2_SIGNIFICANT_ACCOUNTING_POLIC

2. SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
2. SIGNIFICANT ACCOUNTING POLICIES	Use of Estimates
	The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant areas where estimates are used include the allowance for doubtful accounts, inventory valuation and input variables for Black-Scholes, Monte Carlo simulations and Lattice Model calculations.
	Principles of Consolidation
	The accompanying consolidated financial statements include the accounts of Guided Therapeutics, Inc. and its wholly owned subsidiary.
	Accounting Standard Updates
	In May 2014, the FASB issued ASU 2014-09, “Revenue from Contracts with Customers,” (“ASU 2014-09”). ASU 2014-09 outlines a new, single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. This new revenue recognition model provides a five step analysis in determining when and how revenue is recognized. The new model will require revenue recognition to depict the transfer of promised goods or services to customers in an amount that reflects the consideration a company expects to receive in exchange for those goods or services. ASU 2014-09 is effective for reporting periods beginning after December 15, 2016, and early adoption is not permitted. The Company is evaluating the impact that adoption of this guidance will have on the determination or reporting of its financial results.
	In June 2014, the FASB issued ASU 2014-12, “Accounting for Share-Based Payments When the Terms of an Award Provide that a Performance Target Could be Achieved after the Requisite Service Period,” (“ASU 2014-12”). ASU 2014-12 requires that a performance target that affects vesting, and that could be achieved after the requisite service period, be treated as a performance condition. As such, the performance target should not be reflected in estimating the grant date fair value of the award. ASU 2014-12 is effective for the reporting periods beginning after December 15, 2015. Early adoption is permitted. The Company is evaluating the impact that adoption of this guidance will have on the determination or reporting of its financial results.
	In August 2014, the FASB issued ASU 2014-15, “Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern,” (“ASU 2014-15”). ASU 2014-15 requires management to perform interim and annual assessments of an entity’s ability to continue as a going concern for a one year period subsequent to the date of the financial statements, as entity must provide certain disclosures if conditions or events raise substantial doubt about the entity’s ability to continue as a going concern. The guidance is effective for all entities for the first annual period ending after December 15, 2016 and interim periods thereafter, with early adoption permitted. The Company is evaluating the impact that adoption of this guidance will have on the determination or reporting of its financial results.
	Except as noted above, the guidance issued by the FASB during the current year is not expected to have a material effect on the Company’s consolidated financial statements.
	Cash Equivalents
	The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be a cash equivalent.
	Accounts Receivable
	The Company performs periodic credit evaluations of its customers’ financial conditions and generally does not require collateral. The Company reviews all outstanding accounts receivable for collectability on a quarterly basis. An allowance for doubtful accounts is recorded for any amounts deemed uncollectable. The Company does not accrue interest receivable on past due accounts receivable.
	Concentrations of Credit Risk
	The Company, from time to time during the years covered by these consolidated financial statements, may have bank balances in excess of its insured limits. Management has deemed this a normal business risk.
	The Company performs periodic credit evaluations of its customers’ financial conditions and generally does not require collateral. The Company reviews all outstanding accounts receivable for collectability on a quarterly basis. An allowance for doubtful accounts is recorded for any amounts deemed uncollectable. The Company does not accrue interest receivable on past due accounts receivable.
	Inventory Valuation
	All inventories are stated at lower of cost or market, with cost determined substantially on a “first-in, first-out” basis.  Selling, general, and administrative expenses are not inventoried, but are charged to expense when purchased. At December 31, 2014 and December 31, 2013, our inventories were as follows (in thousands):
				Year Ended December 31,
				2014			2013
		Raw materials	$	884		$	1,013
		Work in process		304			268
		Finished goods		136			96
		Inventory reserve		(144	)		(184	)
		Total	$	1,180		$	1,193
	Property and Equipment
	Property and equipment are recorded at cost. Depreciation is computed using the straight-line method over estimated useful lives of three to seven years. Leasehold improvements are depreciated at the shorter of the useful life of the asset or the remaining lease term. Depreciation expense is included in general and administrative expense on the statement of operations. Expenditures for repairs and maintenance are expensed as incurred. Property and equipment are summarized as follows at December 31, 2014 and 2013 (in thousands):
				Year Ended December 31,
				2014			2013
		Equipment	$	1,391		$	1,277
		Software		737			737
		Furniture and fixtures		124			124
		Leasehold Improvement		180			189
				2,432			2,327
		Less accumulated depreciation		(1,845	)		(1,407	)
		Total	$	587		$	920
	Debt Issuance Costs
	Debt issuance costs incurred in securing the Company’s financing arrangements are capitalized and amortized over the term of the debt. Deferred financing costs are included in other long term assets.
	Other Assets
	Other assets primarily consist of long-term deposits for various tooling projects that are being constructed for the Company.
	At December 31, 2014 and 2013, such balances were approximately $72,000 and $326,000, respectively.
	Patent Costs (Principally Legal Fees)
	Costs incurred in filing, prosecuting, and maintaining patents are recurring, and expensed as incurred. Maintaining patents are expensed as incurred as the Company has not yet received FDA approval and recovery of these costs is uncertain. Such costs aggregated approximately $50,000 and $75,000 in 2014 and 2013, respectively.
	Accrued Liabilities
	Accrued liabilities are summarized as follows at December 31, 2014 and 2013 (in thousands):
			As of
			December 31,
			2014			2013
		Accrued compensation	$	447		$	426
		Accrued professional fees		203			116
		Deferred rent		54			68
		Accrued warranty		119			58
		Accrued vacation		144			—
		Other accrued expenses		48			55
		Total	$	1,015		$	723
	Revenue Recognition
	Revenue from the sale of the Company’s products is recognized upon shipment of such products to its customers. The Company recognizes revenue from contracts on a straight line basis, over the terms of the contracts. The Company recognizes revenue from grants based on the grant agreements, at the time the expenses are incurred.
	Significant Customers
	In 2014 and 2013, the majority of the Company’s revenues were from two and three customers, respectively. Revenue from these customers totaled approximately $414,000 or 50% and approximately $653,000 or 65% of total revenue for the year ended December 31, 2014 and 2013, respectively. Accounts receivable due from those customers represents 17% and 27% as of December 31, 2014 and 2013, respectively.
	Deferred Revenue
	The Company defers payments received as revenue until earned based on the related contracts on a straight line basis, over the terms of the contract.
	Research and Development
	Research and development expenses consist of expenditures for research conducted by the Company and payments made under contracts with consultants or other outside parties and costs associated with internal and contracted clinical trials. All research and development costs are expensed as incurred.
	Income Taxes
The Company uses the liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on differences between the financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. Management provides valuation allowances against the deferred tax assets for amounts that are not considered more likely than not to be realized.
Uncertain Tax Positions
Effective January 1, 2007 the Company adopted ASC guidance regarding accounting for uncertainty in income taxes. This guidance clarifies the accounting for income taxes by prescribing the minimum recognition threshold an income tax position is required to meet before being recognized in the financial statements and applies to all income tax positions.  Each income tax position is assessed using a two-step process.  A determination is first made as to whether it is more likely than not that the income tax position will be sustained, based upon technical merits, upon examination by the taxing authorities.  If the income tax position is expected to meet the more likely than not criteria, the benefit recorded in the financial statements equals the largest amount that is greater than 50% likely to be realized upon its ultimate settlement.  At December 31, 2014 and 2013, there were no uncertain tax positions.
The Company is current with its federal and applicable state tax returns filings. Although we have been experiencing recurring losses, we are obligated to file tax returns for compliance with Internal Revenue Service (“IRS”) regulations and that of applicable state jurisdictions. As of December 31, 2014, the Company has approximately $68.4 million of net operating loss eligible to be carried forward for tax purposes at federal and applicable states level.
None of the Company’s federal or state income tax returns are currently under examination by the IRS or state authorities.  However, fiscal years 2011 and later remain subject to examination by the IRS and applicable states.
Warrants
The Company has issued warrants, which allow the warrant holder to purchase one share of stock at a specified price for a specified period of time. The Company records equity instruments including warrants issued to non-employees based on the fair value at the date of issue. The fair value of warrants classified as equity instruments at the date of issuance is estimated using the Black-Scholes Model. The fair value of warrants classified as liabilities at the date of issuance is estimated using the Monte Carlo Simulation model.
Stock Based Compensation
The Company records compensation expense related to options granted to non-employees based on the fair value of the award.
Compensation cost is recorded as earned for all unvested stock options outstanding at the beginning of the first year based upon the grant date fair value estimates, and for compensation cost for all share-based payments granted or modified subsequently based on fair value estimates.
For the years ended December 31, 2014 and 2013, share-based compensation for options attributable to employees and officers were approximately $886,000 and $824,000, respectively. These amounts have been included in the Company’s statements of operations. Compensation costs for stock options which vest over time are recognized over the vesting period. As of December 31, 2014, the Company had approximately $568,000 of unrecognized compensation costs related to granted stock options to be recognized over the remaining vesting period of approximately three years.

3_Fair_Value_of_Financial_Inst

3. Fair Value of Financial Instruments	12 Months Ended
	Dec. 31, 2014
Fair Value Disclosures [Abstract]
3. Fair Value of Financial Instruments	The guidance for fair value measurements, ASC820, Fair Value Measurements and Disclosures, establishes the authoritative definition of fair value, sets out a framework for measuring fair value, and outlines the required disclosures regarding fair value measurements. Fair value is the price that would be received to sell an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. The Company uses a three-tier fair value hierarchy based upon observable and non-observable inputs as follow:
		·	Level 1 – Quoted market prices in active markets for identical assets and liabilities;
		·	Level 2 – Inputs, other than level 1 inputs, either directly or indirectly observable; and
		·	Level 3 – Unobservable inputs developed using internal estimates and assumptions (there is little or no market date) which reflect those that market participants would use.
	The Company records its derivative activities at fair value, which consisted of warrants as of December 31, 2014. The fair value of the warrants was estimated using the Monte Carlo Simulation model. Gains and losses from derivative contracts are included in net gain (loss) from derivative contracts in the statement of operations. The fair value of the Company’s derivative warrants is classified as a Level 3 measurement, since unobservable inputs are used in the valuation.
	The following table presents the fair value for those liabilities measured on a recurring basis as of December 31, 2014 and 2013:
	FAIR VALUE MEASUREMENTS ( In Thousands)
	Description		Level 1		Level 2		Level 3			Total			Asset			Date
													(Liability)
													Total
	Public Offering warrants		$	—	$	—	$	(587	)	$	(587	)	$	(587	)		31-Dec-14
	Series B Warrants		$	—	$	—	$	(1,483	)	$	(1,483	)	$	1,483	)		31-Dec-14
	Total 2014		$	—	$	—	$	(2,070	)	$	(2,070	)	$	(2,070	)
	Series B Warrants		$	—	$	—	$	1,548	)	$	(1,548	)	$	(1,548	)		31-Dec-13

4_Stockholders_Equity

4. Stockholders Equity	12 Months Ended
	Dec. 31, 2014
Equity [Abstract]
4. Stockholders’ Equity	Common Stock
	The Company has authorized 195 million shares of common stock with $0.001 par value, of which 96.9 million were issued and outstanding as of December 31, 2014. For the year ended December 31, 2013, there were 145 million authorized shares of common stock, of which 70.5 million were issued and outstanding.
	For the year ended December 31, 2014, the Company issued 26,409,893 shares of common stock as listed below:
	Public Offering - Issuance - For Cash	8,985,410
	Public Offering - Issuance - For Debt Repayment	7,800,005
	Reg. S - New Issuance - For Cash	651,042
	Series B Conversion	2,311,089
	Series B Dividends	342,389
	Commitment Shares / 2014 Senior Convertible Notes	321,820
	2014 Senior Convertible Note	2,783,959
	Option Exercised	242,439
	Warrant  Exercised	200,000
	Board Compensation	771,740
	Restricted Shares CEO 2014	2,000,000
	Total	26,409,893
	Preferred Stock; Series B Convertible Preferred Stock
	The Company has authorized 5,000,000 shares of preferred stock with a $.001 par value. The board of directors has the authority to issue these shares and to set dividends, voting and conversion rights, redemption provisions, liquidation preferences, and other rights and restrictions. The board of directors designated 525,000 shares of preferred stock as redeemable convertible preferred stock, none of which remain outstanding, and 3,000 shares of preferred stock as Series B Preferred Stock, of which 1,277 and 2,147 shares were issued and outstanding as of December 31, 2014 and 2013, respectively.
	Pursuant to the terms of the Series B Preferred Stock set forth in the Certificate of Designations, Preferences and Rights designating the Preferred Stock (the “Preferred Stock Designation”), shares of Series B Preferred Stock are convertible into common stock by their holder at any time, and will be mandatorily convertible upon the achievement of certain conditions, including the receipt of certain approvals from the U.S. Food and Drug Administration and the achievement by the Company of specified average trading prices and volumes for the common stock. The original conversion price was $0.68 per share, such that each share of Preferred Stock would convert into 1,471 shares of common stock, subject to customary adjustments, including any accrued but unpaid dividends and pursuant to certain anti-dilution provisions, as set forth in the Preferred Stock Designation. As a result of anti-dilution provisions, the current conversion price is set at $0.15 per share, such that each share of Preferred Stock would convert into 6,676 shares of common stock.
	Holders of the Series B Preferred Stock are entitled to quarterly dividends at an annual rate of 5.0%, for the quarter ended December 31, 2014, and at an annual rate of 10.0% thereafter, in each case, payable in cash or, subject to certain conditions, common stock, at the Company’s option. Accrued dividends totaled approximately $32,500 at December 31, 2014. Each share of Series B Preferred Stock is entitled to a number of votes equal to the number of shares of common stock into which the Series B Preferred Stock is convertible. As long as shares of the Series B Preferred Stock are outstanding, and until the receipt of certain approvals from the U.S. Food and Drug Administration and the achievement by the Company of specified average trading prices and volumes for the common stock, the Company may not incur indebtedness for borrowed money secured by the Company’s intellectual property or in excess of $2.0 million without the prior consent of the holders of two-thirds of the outstanding shares of Series B Preferred Stock. The Company may redeem the Series B Preferred Stock after the second anniversary of issuance, subject to certain conditions. Upon the Company’s liquidation or sale to or merger with another corporation, each share of Series B Preferred Stock will be entitled to a liquidation preference of $1,000 per share, plus any accrued but unpaid dividends.
	The Series B Preferred Stock was issued with Tranche A warrants to purchase 1,858,089 shares of common stock and Tranche B warrants purchasing 1,858,088 shares of common stock, both at an exercise price of $1.08 per share. Pursuant to the terms of the Tranche B warrants, their exercise price will be reduced, and the number of shares of common stock into which those warrants are exercisable will be increased, if the Company issues shares at a price below the then-current exercise price. The exercise price of Tranche B warrants is currently $0.15 per share, convertible into 13,196,019 shares of common stock. As a result of these provisions, the Company is required to account for the warrants as a liability recorded at fair value each period. The Company values the warrants using a Monte Carlo Simulation model. Of the $2.6 million in proceeds from issuance of the Series B Preferred Stock, the Company originally allocated $873,000 to the fair value of the warrants. At December 31, 2014, the fair value of these warrants was approximately $1.5 million.
	Stock Options
	Under the Company’s 1995 Stock Plan (the “Plan”), a total of 6,314,824 shares remained available at December 31, 2014 and 6,940,395 shares were subject to stock options outstanding as of that date, bringing the total number of shares subject to stock options outstanding and those remaining available for issue to 13,255,219 shares of common stock as of December 31, 2014. The Plan allows the issuance of incentive stock options, nonqualified stock options, and stock purchase rights. The exercise price of options is determined by the Company’s board of directors, but incentive stock options must be granted at an exercise price equal to the fair market value of the Company’s common stock as of the grant date. Options historically granted have generally become exercisable over four years and expire ten years from the date of grant.
	The fair value of stock options granted in 2014 and 2013 were estimated using the Black-Scholes option pricing model. A summary of the assumptions used in determining the fair value of options follows:
				2014				2013
		Expected volatility			157.7	%			174	%
		Expected option life in years			9.98				10
		Expected dividend yield			0	%			0	%
		Risk-free interest rate			2.55	%			1.87	%
		Weighted average fair value per option at grant date		$	0.4			$	0.69
	Application of the Black-Scholes option pricing model involves assumptions that are judgmental and affect compensation expense. Historical information is the primary basis for the selection of expected volatility, expected option life and expected dividend yield. Expected volatility is based on the most recent historical period equal to the expected life of the option. The risk-free interest rate is based on yields of U.S. Treasury zero-coupon issues with a term equal to the expected life of the option on the date the stock options were granted.
	Stock option activity for each of the two years ended December 31 is as follows:
			2014								2013
							Weighted							Weighted
							Average							Average
							Exercise							Exercise
			Shares				Price				Shares			Price
	Outstanding at beginning of year			6,531,192			$	0.68				6,463,206		$	0.67
	Options granted			754,761			$	0.4				977,276		$	0.5
	Options exercised			(242,439	)		$	0.32				(580,540	)	$	0.31
	Options expired/forfeited			(103,119	)		$	0.68				(328,750	)	$	1.15
	Outstanding at end of year			6,940,395			$	0.66				6,531,192		$	0.66
	Options vested and exercisable at year-end			5,988,119			$	0.66				5,463,963		$	0.58
	Options available for grant at year-end			6,314,824								6,724,027
	Aggregate intrinsic value – options exercised		$	49,675							$	236,059
	Aggregate intrinsic value – options outstanding		$	494,119							$	625,412
	Aggregate intrinsic value – options vested and		$	612,946							$	612,946
	exercisable
	Options unvested, balance at beginning of year (1)			1,067,229			$	1.12				1,819,087		$	1.18
	Options granted (1)			754,761			$	0.4				977,276		$	0.5
	Vested (1)			(766,595	)		$	0.66				(1,582,034	)	$	0.8
	Cancelled/Forfeited			(103,119	)		$	0.68				(147,100		$	1.22
	Balance, end of period (1)			952,276								1,067,229		$	1.12
	__________________
		-1	Includes awards not captured in valuation fragments
	The Company estimates the fair value of stock options using a Black-Scholes valuation model. Key input assumptions used to estimate the fair value of stock options include the expected term, expected volatility of the Company’s common stock, the risk free interest rate, option forfeiture rates, and dividends, if any. The expected term of the options is based upon the historical term until exercise or expiration of all granted options. The expected volatility is derived from the historical volatility of the Company’s stock on the OTCBB market for a period that matches the expected term of the option. The risk-free interest rate is the constant maturity rate published by the U.S. Federal Reserve Board that corresponds to the expected term of the option.
	Warrants
	In November 2013, the Company completed a warrant exchange program, pursuant to which it exchanged warrants exercisable for a total of 3,560,869 shares of common stock, or 99% of the warrants eligible to participate. These exchanges resulted in a deemed dividend of approximately $537,000, reflected as a non-cash disclosure in this financial statement of cash flows.
	The following table summarizes transactions involving the Company’s outstanding warrants to purchase common stock for the year ended December 31, 2014:
				Warrants
				(Underlying Shares)
		Outstanding, January 1, 2014			11,258,939
		Issuances			19,238,727
		Canceled / Expired			(501,512	)
		Exercised			(200,000	)
	Outstanding, December 31, 2014			29,796,154
The Company had the following shares reserved for the warrants as of December 31, 2014:
	Warrants		Exercise Price	Expiration Date
	(Underlying Shares)
	3,590,522	-1	$0.8000 per share	1-Mar-15
	6,790	-2	$1.0100 per share	10-Sep-15
	439,883	-3	$0.6800 per share	31-Mar-16
	285,186	-4	$1.0500 per share	20-Nov-16
	1,858,089	-5	$1.0800 per share	23-May-18
	13,196,103	(5)(6)	$0.1498 per share	23-May-18
	200,000	-7	$0.5000 per share	23-Apr-19
	561,798	-7	$0.4500 per share	22-May-19
	184,211	-8	$0.3800 per share	10-Sep-19
	325,521	-9	$0.4601 per share	27-Sep-19
	8,392,707	-10	$0.2250 per share	2-Dec-19
	755,344	-11	$0.2812 per share	2-Dec-19
-1	Consists of outstanding warrants issued in conjunction with a June 2012 warrant exchange program.
-2	Consists of outstanding warrants issued in conjunction with a September 2010 private placement.
-3	Consists of outstanding warrants issued in conjunction with a buy-back of a minority interest in Interscan in December 2012, which were issued in February 2014.
-4	Consists of outstanding warrants issued in conjunction with a November 2011 private placement.
-5	Consists of outstanding warrants issued in conjunction with a May 2013 private placement.
-6	Underlying shares increased from 1,858,089 to 9,138,141, and per share exercise price decreased from $1.08 to $0.2196, pursuant to the anti-dilution provisions in the warrants, as a result of conversions of the senior convertible notes.
-7	Consists of warrants issued to the placement agent in connection with the private placement of our senior convertible notes.
-8	Consists of outstanding warrants issued to a placement agent in conjunction with the secured note offering.
-9	Consists of outstanding warrants issued in conjunction with the Regulation S offering.
-10	Consists of outstanding warrants issued in conjunction with the 2014 public offering.
-11	Consists of outstanding warrants issued to the Placement Agent in conjunction with the 2014 public offering.

5_Income_Taxes

5. Income Taxes	12 Months Ended
	Dec. 31, 2014
Income Tax Disclosure [Abstract]
5. Income Taxes	The Company has incurred net operating losses (“NOLs”) since inception. As of December 31, 2014, the Company had NOL carryforwards available through 2034 of approximately $68.4 million to offset its future income tax liability. The NOL carryforwards began to expire in 2008. The Company has recorded a valuation allowance for all deferred tax assets related to the NOLs. Utilization of existing NOL carry forwards may be limited in future years based on significant ownership changes. The Company is in the process of analyzing its NOLs and has not determined if it is subject to any restrictions in the Internal Revenue Code that could limit the future use of NOL.
	Components of deferred taxes are as follows at December 31 (in thousands):
			2014			2013
		Deferred tax assets:
		Net operating loss carry forwards	$	466		$	287
		Deferred tax liabilities:
		Intangible assets and other		25,994			22,737
				26,460			23,025
		Valuation allowance		(26,460	)		(23,025	)
			$	0		$	0
	The following is a summary of the items that caused recorded income taxes to differ from taxes computed using the statutory federal income tax rate for the years ended December 31:
			2014			2013
		Statutory federal tax rate		34	%		34	%
		State taxes, net of federal benefit		4			4
		Nondeductible expenses		—			—
		Valuation allowance		(38	)		(38	)
				0	%		0	%

6_Commitments_and_Contingencie

6. Commitments and Contingencies	12 Months Ended
	Dec. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
6. Commitments and Contingencies	Operating Leases
	In December 2009, the Company moved its offices, which comprise its administrative, research and development, marketing and production facilities to 5835 Peachtree Corners East, Suite D, Norcross, Georgia 30092. The Company leases approximately 23,000 square feet under a lease that expires in June 2017. The fixed monthly lease expense is approximately $15,000 plus common charges. The Company also leases office and equipment under operating lease agreements with monthly payments of approximately $2,000.  These leases expire at various dates through April 2016.  Future minimum rental payments at December 31, 2014 under non-cancellable operating leases for office space and equipment are as follows (in thousands):
			Amount (,000)
		Year
		2015	$         211
		2016	201
		2017	98
		Total	$        510
	Rental expense was approximately $170, 000 in 2014 and 2013.
	Litigation and Claims
	For the years ended December 31, 2014 and 2013, there was no accrual needed for any potential losses related to pending litigation.
	Contracts
	In February 2013, the Company replaced its existing agreements with Konica Minolta with a new agreement, pursuant to which, subject to the payment of a nominal license fee due upon FDA approval, Konica Minolta has granted the Company a five-year, world-wide, non-transferable and non-exclusive right and license to manufacture and to develop a non-invasive esophageal cancer detection product from Konica Minolta and based on the Company’s biophotonic technology platform. The license permits the Company to use certain related intellectual property of Konica Minolta. In return for the license, the Company has agreed to pay Konica Minolta a royalty for each licensed product the Company sells.

7_License_and_Technology_Agree

7. License and Technology Agreements	12 Months Ended
	Dec. 31, 2014
Notes to Financial Statements
7. License and Technology Agreements	As part of the Company’s efforts to conduct research and development activities and to commercialize potential products, the Company, from time to time, enters into agreements with certain organizations and individuals that further those efforts but also obligate the Company to make future minimum payments or to remit royalties ranging from 1% to 3% of revenue from the sale of commercial products developed from the research. The Company generally is required to make minimum royalty payments for the exclusive license to develop certain technology.

8_NOTES_PAYABLE

8. NOTES PAYABLE	12 Months Ended
	Dec. 31, 2014
Debt Disclosure [Abstract]
8. NOTES PAYABLE	Short Term Notes Payable
	At December 31, 2014, the Company maintained notes payable and accrued interest to related parties totaling $609,000. These notes are short term, straight-line amortizing notes. The notes carry an annual interest rate of between 5% and 10%.
	At December 31, 2014, the Company maintained a note payable to Premium Assignment Corporation, an insurance premium financing company, of approximately $100,000. This note is 10 month straight-line amortizing loan dated June 24, 2014. The note carries annual interest of 4.6%. The balance due to on the Premium Assignment note was approximately $37,000 at December 31, 2014.
	On September 10, 2014, the Company entered into a note purchase agreement with Tonaquint, Inc., pursuant to which the Company sold a secured promissory note to Tonaquint with an initial principal amount of $1,275,000, for a purchase price of $700,000 (an original issue discount of $560,000). The Company may prepay the note at any time. The note is secured by the Company’s current and future accounts receivable and inventory, pursuant to a security agreement entered into in connection with the note purchase agreement. On March 10, 2015, the Company amended the note to extend the maturity until May 10, 2015. See Note 12, Subsequent Events.
	In connection with the offering, the Company issued its placement agent warrants exercisable for 184,211 shares at $0.38 per share, with an expiration date of September 10, 2019.
	Total debt issuance cost capitalized was approximately $130,000. This amount is being amortized over six months. Total amortized expense for the year ended December 31, 2014 was approximately $81,000.
	For the year ended December 31, 2014, the Company recorded amortization of approximately $347,000 on the discount.
	Notes Payable
	At December 31, 2012, the Company was past due on two short-term notes totaling approximately $419,000 of principal and accrued interest. Interest charged on these notes prior to amendment ranged between 15-18%. On February 27, 2013, the Company renegotiated one of the two past due notes. The new note accrued interest at 6% and was paid in full during the quarter ended June 30, 2013. On April 16, 2013, the Company renegotiated the other note. The renegotiated note accrues interest at 9.0%, with a 16.0% default rate, requires monthly payments of $10,000, including interest, and matures November 2015. The balance due on this note was approximately $159,000 and $208,000 at December 31, 2014 and 2013, respectively. As of December 31, 2014, the note is accruing interest at the default rate, of which principal and interest of $130,000 is payable during the year ending December 31, 2015 and $29,000 is payable during the year ending December 31, 2016.
	Convertible debt
	On April 23, 2014, the Company entered into a securities purchase agreement (the “Purchase Agreement”), with Magna Equities II, LLC (formerly Hanover Holdings I, LLC), an affiliate of Magna Group (“Magna”). Pursuant to the Purchase Agreement, the Company sold Magna a 6% senior convertible note with an initial principal amount of $1.5 million and an 18-month term (the “Initial Convertible Note”), for a purchase price of $1.0 million (an approximately 33.3% original issue discount). Additionally, pursuant to the Purchase Agreement, on May 23, 2014 Magna purchased an additional senior convertible note with an initial principal amount of $2.0 million and an 18-month term (the “Additional Convertible Note” and, with the Initial Convertible Note, (the “Convertible Notes”), for a fixed purchase price of $2.0 million.
	Pursuant to the terms of the Initial Convertible Note, $500,000 of the outstanding principal amount (together with any accrued and unpaid interest with respect to such portion) was automatically extinguished (without any cash payment by the Company) upon satisfaction of certain conditions.
	Subject to certain limitations, the Convertible Notes are convertible at any time, in whole or in part, at Magna’s option, into shares of the Company’s common stock, at a conversion price equal to the lesser of $0.55 per share and a discount from the lowest daily volume-weighted average price of the Company’s common stock in the five trading days prior to conversion. Beginning December 19, 2014, the discount is 25%. At no time will Magna be entitled to convert any portion of the Convertible Notes to the extent that after such conversion, Magna (together with its affiliates) would beneficially own more than 9.99% of the outstanding shares of the Company’s common stock as of such date. As long as Magna or its affiliates beneficially own any of the shares issued upon conversion, they may not engage in any “short sale” transactions in the Company’s common stock and may not sell more than the greater of $15,000 or 15% of the trading volume of the common stock in any single trading day.
	The Convertible Notes include customary event of default provisions and a default interest rate of 16%. Upon the occurrence of an event of default, Magna may require the Company to pay in cash the “Event of Default Redemption Price,” which is defined in the Convertible Notes to mean the greater of (i) the product of (A) the amount to be redeemed multiplied by (B) 135% (or 100% if an insolvency related event of default) and (ii) the product of (X) the conversion price in effect at that time multiplied by (Y) the product of (1) 135% (or 100% if an insolvency related event of default) multiplied by (2) the greatest closing sale price of the common stock on any trading day during the period commencing on the date immediately preceding such event of default and ending on the date the Company makes the entire payment required to be made under this provision.
	The Company paid to Magna a commitment fee for entering into the Purchase Agreement in the form of 321,820 shares of common stock. The Company also paid $50,000 of attorneys’ fees and expenses incurred by Magna in connection with the transaction. Total debt issuance costs incurred on the Senior Convertible Note was approximately $844,000. This amount is being amortized over 18 months. Total amortization expense for the year ended was approximately $328,000.
	In connection with the sale of the Convertible Notes, the Company issued its placement agent warrants exercisable for 200,000 shares of common stock at $0.50 per share with an expiration date of April 23, 2019, and warrants exercisable for 561,798 shares of common stock at $0.45 per share with an expiration date of May 22, 2019.
	As of December 31, 2014, the Company had issued a total of 2,783,959 shares of common stock, in conjunction with conversions of the Convertible Notes.
	Loss on Extinguishment of Debt
	As part of our public offering of sale of common stock, consummated on December 2, 2014, the Company repaid approximately $1.4 of debt via the issuance of 7,700,504 shares of common stock and warrants to purchase an additional 3,850,252 shares at an exercise price of $0.225 per share, expiring in December 2, 2019. Pursuant to the convertible note agreement, the Company had to pay a prepayment penalty of 25% of the amount prepaid.  The penalty on the transaction was approximately $325,000 and was charged to loss on extinguishment of debt on the statement of operations for the year ended December 31, 2014.

9_Related_Party_Transactions

9. Related Party Transactions	12 Months Ended
	Dec. 31, 2014
Related Party Transactions [Abstract]
9. Related Party Transactions	At December 31, 2014, the Company maintained notes payable and accrued interest to related parties totaling approximately $609,000. These notes are short term, straight-line amortizing notes.  The notes carry an annual interest rate of between 5% and 10%.
	Our Directors and Officers participated in our public offering dated December 2, 2014 for a total of $182,603 and received 811,571 shares of common stock as well as warrants to purchase an additional 405,786 shares at $0.225, expiring in December 2, 2019.

10_Valuation_and_Qualifying_Ac

10. Valuation and Qualifying Accounts	12 Months Ended
	Dec. 31, 2014
Valuation and Qualifying Accounts [Abstract]
10. Valuation and Qualifying Accounts	Allowance for Doubtful Accounts
	The Company has the following allowances for doubtful accounts (in thousands):
	Year Ended December 31,
			2014			2013
		Beginning balance	$	18		$	12
		Additions / (Adjustments)		58			6
		Balance	$	76		$	18
	Inventory Reserves
	The Company has the following reserves for inventory balance (in thousands):
			Year Ended December 31,
			2014			2013
		Beginning balance	$	184		$	52
		Additions / (Adjustments)		(40	)		132
		Balance	$	144		$	184

11_LOSS_PER_COMMON_SHARE

11. LOSS PER COMMON SHARE	12 Months Ended
	Dec. 31, 2014
Earnings Per Share [Abstract]
11. LOSS PER COMMON SHARE	Basic net loss per share attributable to common stockholders amounts are computed by dividing the net loss plus preferred stock dividends and deemed dividends on preferred stock by the weighted average number of shares outstanding during the period.

12_Subsequent_Events

12. Subsequent Events	12 Months Ended
	Dec. 31, 2014
Notes to Financial Statements
12. Subsequent Events	Between January 1, 2015 and March 25, 2015, we received approximately $17,000 from the Company’s officers as short-term advances.
	On February 2, 2015, we received $70,000 from an investor as a deposit for the purchase of LuViva devices for exportation. As of March 25, 2015, negotiation of a definitive purchase agreement was on-going.
	On March 16, 2015 and March 19, 2015, the Company entered into subscription agreements with certain accredited investors, pursuant to which we agreed to sell an aggregate of 4.0 million shares of our common stock and warrants to purchase an additional 2.0 million shares, for an aggregate purchase price of $720,000 in a private placement not involving a public offering under Section 4(a)(2) of the Securities Act. As of March 19, 2015, the Company had consummated $320,000 of the total transaction and we expect to consummate the remainder by the end of the first quarter of 2015. The warrants are immediately exercisable, have an exercise price per share of $0.255 and expire three years from the date of issuance.
	On March 10, 2015, the Company amended the Tonaquint note to extend the maturity until May 10, 2015. During the extension, interest will accrue on the note at a rate of the lesser of 18% per year or the maximum rate permitted by applicable law. In addition, while the note remains outstanding, Tonaquint will have the right to convert up to $150,000 of the outstanding balance of the note into shares of the Company’s common stock, at a conversion price per share equal to the lower of (1) $0.25 and (2) 75% of the lowest daily volume weighted average price per share of the common stock during the five business days prior to conversion. If the conversion price would be lower than $0.15 per share, the Company has the option of delivering the conversion amount in cash in lieu of shares.

2_SIGNIFICANT_ACCOUNTING_POLIC1

2. SIGNIFICANT ACCOUNTING POLICIES (Policies)	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
Use of Estimates	The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant areas where estimates are used include the allowance for doubtful accounts, inventory valuation and input variables for Black-Scholes, Monte Carlo simulations and Lattice Model calculations.
Principles of Consolidation	The accompanying consolidated financial statements include the accounts of Guided Therapeutics, Inc. and its wholly owned subsidiary.
Accounting Standards Updates	In May 2014, the FASB issued ASU 2014-09, “Revenue from Contracts with Customers,” (“ASU 2014-09”). ASU 2014-09 outlines a new, single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. This new revenue recognition model provides a five step analysis in determining when and how revenue is recognized. The new model will require revenue recognition to depict the transfer of promised goods or services to customers in an amount that reflects the consideration a company expects to receive in exchange for those goods or services. ASU 2014-09 is effective for reporting periods beginning after December 15, 2016, and early adoption is not permitted. The Company is evaluating the impact that adoption of this guidance will have on the determination or reporting of its financial results.
	In June 2014, the FASB issued ASU 2014-12, “Accounting for Share-Based Payments When the Terms of an Award Provide that a Performance Target Could be Achieved after the Requisite Service Period,” (“ASU 2014-12”). ASU 2014-12 requires that a performance target that affects vesting, and that could be achieved after the requisite service period, be treated as a performance condition. As such, the performance target should not be reflected in estimating the grant date fair value of the award. ASU 2014-12 is effective for the reporting periods beginning after December 15, 2015. Early adoption is permitted. The Company is evaluating the impact that adoption of this guidance will have on the determination or reporting of its financial results.
	In August 2014, the FASB issued ASU 2014-15, “Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern,” (“ASU 2014-15”). ASU 2014-15 requires management to perform interim and annual assessments of an entity’s ability to continue as a going concern for a one year period subsequent to the date of the financial statements, as entity must provide certain disclosures if conditions or events raise substantial doubt about the entity’s ability to continue as a going concern. The guidance is effective for all entities for the first annual period ending after December 15, 2016 and interim periods thereafter, with early adoption permitted. The Company is evaluating the impact that adoption of this guidance will have on the determination or reporting of its financial results.
	Except as noted above, the guidance issued by the FASB during the current year is not expected to have a material effect on the Company’s consolidated financial statements.
Cash Equivalents	The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be a cash equivalent.
Accounts Receivable	The Company performs periodic credit evaluations of its customers’ financial conditions and generally does not require collateral. The Company reviews all outstanding accounts receivable for collectability on a quarterly basis. An allowance for doubtful accounts is recorded for any amounts deemed uncollectable. The Company does not accrue interest receivable on past due accounts receivable.
Concentration of Credit Risk	The Company, from time to time during the years covered by these consolidated financial statements, may have bank balances in excess of its insured limits. Management has deemed this a normal business risk.
	The Company performs periodic credit evaluations of its customers’ financial conditions and generally does not require collateral. The Company reviews all outstanding accounts receivable for collectability on a quarterly basis. An allowance for doubtful accounts is recorded for any amounts deemed uncollectable. The Company does not accrue interest receivable on past due accounts receivable.
Inventory Valuation	All inventories are stated at lower of cost or market, with cost determined substantially on a “first-in, first-out” basis.  Selling, general, and administrative expenses are not inventoried, but are charged to expense when purchased. At December 31, 2014 and December 31, 2013, our inventories were as follows (in thousands):
				Year Ended December 31,
				2014			2013
		Raw materials	$	884		$	1,013
		Work in process		304			268
		Finished goods		136			96
		Inventory reserve		(144	)		(184	)
		Total	$	1,180		$	1,193
Property and equipment	Property and equipment are recorded at cost. Depreciation is computed using the straight-line method over estimated useful lives of three to seven years. Leasehold improvements are depreciated at the shorter of the useful life of the asset or the remaining lease term. Depreciation expense is included in general and administrative expense on the statement of operations. Expenditures for repairs and maintenance are expensed as incurred. Property and equipment are summarized as follows at December 31, 2014 and 2013 (in thousands):
				Year Ended December 31,
				2014			2013
		Equipment	$	1,391		$	1,277
		Software		737			737
		Furniture and fixtures		124			124
		Leasehold Improvement		180			189
				2,432			2,327
		Less accumulated depreciation		(1,845	)		(1,407	)
		Total	$	587		$	920
Debt issuance cost	Debt issuance costs incurred in securing the Company’s financing arrangements are capitalized and amortized over the term of the debt. Deferred financing costs are included in other long term assets.
Other Assets	Other assets primarily consist of long-term deposits for various tooling projects that are being constructed for the Company.
	At December 31, 2014 and 2013, such balances were approximately $72,000 and $326,000, respectively.
Patent Costs (Principally Legal Fees)	Costs incurred in filing, prosecuting, and maintaining patents are recurring, and expensed as incurred. Maintaining patents are expensed as incurred as the Company has not yet received FDA approval and recovery of these costs is uncertain. Such costs aggregated approximately $50,000 and $75,000 in 2014 and 2013, respectively.
Accrued Liabilities	Accrued liabilities are summarized as follows at December 31, 2014 and 2013 (in thousands):
			As of
			December 31,
			2014			2013
		Accrued compensation	$	447		$	426
		Accrued professional fees		203			116
		Deferred rent		54			68
		Accrued warranty		119			58
		Accrued vacation		144			—
		Other accrued expenses		48			55
		Total	$	1,015		$	723
Revenue Recognition	Revenue from the sale of the Company’s products is recognized upon shipment of such products to its customers. The Company recognizes revenue from contracts on a straight line basis, over the terms of the contracts. The Company recognizes revenue from grants based on the grant agreements, at the time the expenses are incurred.
Significant Customers	In 2014 and 2013, the majority of the Company’s revenues were from two and three customers, respectively. Revenue from these customers totaled approximately $414,000 or 50% and approximately $653,000 or 65% of total revenue for the year ended December 31, 2014 and 2013, respectively. Accounts receivable due from those customers represents 17% and 27% as of December 31, 2014 and 2013, respectively.
Deferred Revenue	The Company defers payments received as revenue until earned based on the related contracts on a straight line basis, over the terms of the contract.
Research and Development	Research and development expenses consist of expenditures for research conducted by the Company and payments made under contracts with consultants or other outside parties and costs associated with internal and contracted clinical trials. All research and development costs are expensed as incurred.
Income Taxes	The Company uses the liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on differences between the financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. Management provides valuation allowances against the deferred tax assets for amounts that are not considered more likely than not to be realized.
Uncertain Tax Positions	Effective January 1, 2007 the Company adopted ASC guidance regarding accounting for uncertainty in income taxes. This guidance clarifies the accounting for income taxes by prescribing the minimum recognition threshold an income tax position is required to meet before being recognized in the financial statements and applies to all income tax positions.  Each income tax position is assessed using a two-step process.  A determination is first made as to whether it is more likely than not that the income tax position will be sustained, based upon technical merits, upon examination by the taxing authorities.  If the income tax position is expected to meet the more likely than not criteria, the benefit recorded in the financial statements equals the largest amount that is greater than 50% likely to be realized upon its ultimate settlement.  At December 31, 2014 and 2013, there were no uncertain tax positions.
	The Company is current with its federal and applicable state tax returns filings. Although we have been experiencing recurring losses, we are obligated to file tax returns for compliance with Internal Revenue Service (“IRS”) regulations and that of applicable state jurisdictions. As of December 31, 2014, the Company has approximately $68.4 million of net operating loss eligible to be carried forward for tax purposes at federal and applicable states level.
	None of the Company’s federal or state income tax returns are currently under examination by the IRS or state authorities.  However, fiscal years 2011 and later remain subject to examination by the IRS and applicable states.
Warrants	The Company has issued warrants, which allow the warrant holder to purchase one share of stock at a specified price for a specified period of time. The Company records equity instruments including warrants issued to non-employees based on the fair value at the date of issue. The fair value of warrants classified as equity instruments at the date of issuance is estimated using the Black-Scholes Model. The fair value of warrants classified as liabilities at the date of issuance is estimated using the Monte Carlo Simulation model.
Stock Based Compensation	The Company records compensation expense related to options granted to non-employees based on the fair value of the award.
	Compensation cost is recorded as earned for all unvested stock options outstanding at the beginning of the first year based upon the grant date fair value estimates, and for compensation cost for all share-based payments granted or modified subsequently based on fair value estimates.
	For the years ended December 31, 2014 and 2013, share-based compensation for options attributable to employees and officers were approximately $886,000 and $824,000, respectively. These amounts have been included in the Company’s statements of operations. Compensation costs for stock options which vest over time are recognized over the vesting period. As of December 31, 2014, the Company had approximately $568,000 of unrecognized compensation costs related to granted stock options to be recognized over the remaining vesting period of approximately three years.

2_SIGNIFICANT_ACCOUNTING_POLIC2

2. SIGNIFICANT ACCOUNTING POLICIES (Tables)	12 Months Ended
	Dec. 31, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Inventory Valuation				Year Ended December 31,
				2014			2013
		Raw materials	$	884		$	1,013
		Work in process		304			268
		Finished goods		136			96
		Inventory reserve		(144	)		(184	)
		Total	$	1,180		$	1,193
Property and Equipment				Year Ended December 31,
				2014			2013
		Equipment	$	1,391		$	1,277
		Software		737			737
		Furniture and fixtures		124			124
		Leasehold Improvement		180			189
				2,432			2,327
		Less accumulated depreciation		(1,845	)		(1,407	)
		Total	$	587		$	920
Accrued Liabilities			As of
			December 31,
			2014			2013
		Accrued compensation	$	447		$	426
		Accrued professional fees		203			116
		Deferred rent		54			68
		Accrued warranty		119			58
		Accrued vacation		144			—
		Other accrued expenses		48			55
		Total	$	1,015		$	723

3_Fair_Value_of_Financial_Inst1

3. Fair Value of Financial Instruments (Tables)	12 Months Ended
	Dec. 31, 2014
Fair Value Of Financial Instruments Tables
Schedule of fair value measurements	Description	Level 1		Level 2		Level 3			Total			Asset			Date
												(Liability)
												Total
	Public Offering warrants	$	—	$	—	$	(587	)	$	(587	)	$	(587	)		31-Dec-14
	Series B Warrants	$	—	$	—	$	(1,483	)	$	(1,483	)	$	1,483	)		31-Dec-14
	Total 2014	$	—	$	—	$	(2,070	)	$	(2,070	)	$	(2,070	)
	Series B Warrants	$	—	$	—	$	1,548	)	$	(1,548	)	$	(1,548	)		31-Dec-13

4_Stockholders_Equity_Tables

4. Stockholders Equity (Tables)	12 Months Ended
	Dec. 31, 2014
Equity [Abstract]
Common stock activity	Public Offering - Issuance - For Cash	8,985,410
	Public Offering - Issuance - For Debt Repayment	7,800,005
	Reg. S - New Issuance - For Cash	651,042
	Series B Conversion	2,311,089
	Series B Dividends	342,389
	Commitment Shares / 2014 Senior Convertible Notes	321,820
	2014 Senior Convertible Note	2,783,959
	Option Exercised	242,439
	Warrant  Exercised	200,000
	Board Compensation	771,740
	Restricted Shares CEO 2014	2,000,000
	Total	26,409,893
Schedule of assumptions used to determine fair value of stock options				2014				2013
		Expected volatility			157.7	%			174	%
		Expected option life in years			9.98				10
		Expected dividend yield			0	%			0	%
		Risk-free interest rate			2.55	%			1.87	%
		Weighted average fair value per option at grant date		$	0.4			$	0.69
Stock option activity			2014								2013
							Weighted							Weighted
							Average							Average
							Exercise							Exercise
			Shares				Price				Shares			Price
	Outstanding at beginning of year			6,531,192			$	0.68				6,463,206		$	0.67
	Options granted			754,761			$	0.4				977,276		$	0.5
	Options exercised			(242,439	)		$	0.32				(580,540	)	$	0.31
	Options expired/forfeited			(103,119	)		$	0.68				(328,750	)	$	1.15
	Outstanding at end of year			6,940,395			$	0.66				6,531,192		$	0.66
	Options vested and exercisable at year-end			5,988,119			$	0.66				5,463,963		$	0.58
	Options available for grant at year-end			6,314,824								6,724,027
	Aggregate intrinsic value – options exercised		$	49,675							$	236,059
	Aggregate intrinsic value – options outstanding		$	494,119							$	625,412
	Aggregate intrinsic value – options vested and		$	612,946							$	612,946
	exercisable
	Options unvested, balance at beginning of year (1)			1,067,229			$	1.12				1,819,087		$	1.18
	Options granted (1)			754,761			$	0.4				977,276		$	0.5
	Vested (1)			(766,595	)		$	0.66				(1,582,034	)	$	0.8
	Cancelled/Forfeited			(103,119	)		$	0.68				(147,100		$	1.22
	Balance, end of period (1)			952,276								1,067,229		$	1.12
Company’s outstanding warrants to purchase common stock				Warrants
				(Underlying Shares)
		Outstanding, January 1, 2014			11,258,939
		Issuances			19,238,727
		Canceled / Expired			(501,512	)
		Exercised			(200,000	)
		Outstanding, December 31, 2014			29,796,154
Schedule of shares reserved for warrants		Warrants		Exercise Price	Expiration Date
		(Underlying Shares)
		3,590,522	-1	$0.8000 per share	1-Mar-15
		6,790	-2	$1.0100 per share	10-Sep-15
		439,883	-3	$0.6800 per share	31-Mar-16
		285,186	-4	$1.0500 per share	20-Nov-16
		1,858,089	-5	$1.0800 per share	23-May-18
		13,196,103	(5)(6)	$0.1498 per share	23-May-18
		200,000	-7	$0.5000 per share	23-Apr-19
		561,798	-7	$0.4500 per share	22-May-19
		184,211	-8	$0.3800 per share	10-Sep-19
		325,521	-9	$0.4601 per share	27-Sep-19
		8,392,707	-10	$0.2250 per share	2-Dec-19
		755,344	-11	$0.2812 per share	2-Dec-19

5_Income_Taxes_Tables

5. Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Components of deferred taxes			2014			2013
		Deferred tax assets:
		Net operating loss carry forwards	$	466		$	287
		Deferred tax liabilities:
		Intangible assets and other		25,994			22,737
				26,460			23,025
		Valuation allowance		(26,460	)		(23,025	)
			$	0		$	0
Income taxes			2014			2013
		Statutory federal tax rate		34	%		34	%
		State taxes, net of federal benefit		4			4
		Nondeductible expenses		—			—
		Valuation allowance		(38	)		(38	)
				0	%		0	%

6_Commitments_and_Contingencie1

6. Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
Schedule of operating leases			Amount (,000)
		Year
		2015	$         211
		2016	201
		2017	98
		Total	$        510

10_Valuation_and_Qualifying_Ac1

10. Valuation and Qualifying Accounts (Tables)	12 Months Ended
	Dec. 31, 2014
Valuation and Qualifying Accounts [Abstract]
Schedule of Allowance for Doubtful Accounts
			Year Ended December 31,
			2014			2013
		Beginning balance	$	18		$	12
		Additions / (Adjustments)		58			6
		Balance	$	76		$	18
Schedule of Inventory Reserves			Year Ended December 31,
			2014			2013
		Beginning balance	$	184		$	52
		Additions / (Adjustments)		(40	)		132
		Balance	$	144		$	184

1_BASIS_OF_PRESENTATION_Detail

1. BASIS OF PRESENTATION (Details Narrative) (USD $)	Dec. 31, 2014
In Thousands, unless otherwise specified
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Accumulated deficit	$113,100
Working capital	$2,800

2_SIGNIFICANT_ACCOUNTING_POLIC3

2. SIGNIFICANT ACCOUNTING POLICIES (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Accounting Policies [Abstract]
Raw materials	$884	$1,013
Work in process	304	268
Finished goods	136	96
Inventory reserve	-144	-184
Total	$1,180	$1,193

2_Summary_of_Significant_Accou

2. Summary of Significant Accounting Policies (Details 1) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Gross Value of property plant and equipment	$2,432	$2,432
Less: accumulated depreciation and amortization	-1,845	2,327
Total property and equipment, net	587	920
Equipment
Gross Value of property plant and equipment	1,391	1,277
Software
Gross Value of property plant and equipment	737	737
Furniture and fixtures
Gross Value of property plant and equipment	124	124
Leasehold improvements
Gross Value of property plant and equipment	$180	$189

2_SIGNIFICANT_ACCOUNTING_POLIC4

2. SIGNIFICANT ACCOUNTING POLICIES (Details 2) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Accrued compensation	$447	$426
Accrued professional fees	203	116
Deferred rent	54	68
Accrued warranty	119	58
Accrued vacation	144	0
Other accrued expenses	48	55
Total	$1,015	$723

2_SIGNIFICANT_ACCOUNTING_POLIC5

2. SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Accounting Policies [Abstract]
Patent Costs	$50,000	$75,000
Other assets	72,000	326,000
Net Operating loss carry forward		$68,400,000

3_Fair_Value_of_Financial_Inst2

3. Fair Value of Financial Instruments (Details)	Dec. 31, 2014	Dec. 31, 2013
Warrants	-2,070
Level 1
Warrants	0
Level 1 | Public Offering Warrants
Warrants	0
Level 1 | Series B Warrants
Warrants	0	0
Level 2
Warrants	0
Level 2 | Public Offering Warrants
Warrants	0
Level 2 | Series B Warrants
Warrants	0	0
Level 3
Warrants	-2,070
Level 3 | Public Offering Warrants
Warrants	-587
Level 3 | Series B Warrants
Warrants	-1,483	-1,548
Public Offering Warrants
Warrants	-587
Series B Warrants
Warrants	-1,483	-1,548

4_Stockholders_Equity_Details_

4. Stockholders’ Equity (Details 0)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Stockholders Equity Details 0
Public Offering - Issuance - For Cash	8,985,410
Public Offering - Issuance - For Debt Repayment	7,800,005
Reg. S - New Issuance - For Cash	651,042
Series B Conversion	2,311,089
Series B Dividends	342,389
Commitment Shares / 2014 Senior Convertible Notes	321,820
2014 Senior Convertible Note	2,783,959
Option Exercised	242,439	-580,540
Warrant  Exercised	200,000
Board Compensation	771,740
Restricted Shares CEO 2014	2,000,000
Total	26,409,893

4_Stockholders_Equity_Details

4. Stockholders’ Equity (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Equity [Abstract]
Expected volatility	157.70%	174.00%
Expected option life in years	9 years 11 months 23 days	10 years
Expected dividend yield	0.00%	0.00%
Risk-free interest rate	2.55%	1.87%
Weighted average fair value per option at grant date	$0.40	$0.69

Recovered_Sheet1

4. STOCKHOLDERS' EQUITY (Details 1) (USD $)	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Number of stock options
Outstanding beginning balance, Shares	6,531,192	6,463,206
Granted, Shares	754,761	977,276
Exercised, Shares	242,439	-580,540
Expired/Forfeited, Shares	-103,119	-328,750
Outstanding ending balance, Shares	6,940,395	6,531,192
Vested and exercisable ending balance	5,988,119	5,463,963
Options available for grant at year-end	6,314,824	6,724,027
Aggregate intrinsic value – options exercised	$49,675	$236,059
Aggregate intrinsic value – options outstanding	494,119	625,412
Aggregate intrinsic value – options vested and Exercisable	612,946	612,946
Weighted average exercise price
Outstanding beginning balance, Weighted average exercise price	$0.66	$0.67
Granted, Weighted average exercise price	$0.40	$0.50
Exercised, Weighted average exercise price	$0.32	$0.31
Expired, Weighted average exercise price	$0.68	$1.15
Outstanding ending balance, Weighted average exercise price	$0.66	$0.66
Vested and exercisable ending balance	$0.66	$0.58
Options Unvested
Options unvested, beginning balance	1,067,229	1,819,087
Options granted	754,761	977,276
Options Vested	-766,595	-1,582,034
Options Cancelled/Forfeited	($103,119)	($147,100)
Balance, end of period	952,276	1,067,229
Options unvested, beginning balance, weighted average exercise price	$1.12	$1.18
Options granted, weighted average exercise price	$0.40	$0.50
Options Vested, weighted average exercise price	$0.66	$0.80
Options Cancelled/Forfeited, weighted average exercise price	$0.68	$1.22
Balance, end of period		$1.12

4_STOCKHOLDERS_EQUITY_Details_1

4. STOCKHOLDERS' EQUITY (Details 2)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Issuances	8,985,410
Exercised	242,439	-580,540
Warrant [Member]
Outstanding beginning balance	11,258,939
Issuances	19,238,727
Canceled / Expired	-501,512
Exercised	-200,000
Outstanding ending balance	29,796,154

4_STOCKHOLDERS_EQUITY_Details_2

4. STOCKHOLDERS' EQUITY (Details 3) (USD $)	12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2014
Warrants 1
Warrants	$3,590,522
Exercise Price	$0.80
Expiration Date	1-Mar-14
Warrants 2
Warrants	6,790
Exercise Price	$1.01
Expiration Date	10-Sep-15
Warrants 3
Warrants	439,883
Exercise Price	$0.68
Expiration Date	31-Mar-16
Warrants 4
Warrants	285,186
Exercise Price	$1.05
Expiration Date	20-Nov-16
Warrants 5
Warrants	1,858,089
Exercise Price	$1.08
Expiration Date	23-May-18
Warrants 6
Warrants	13,196,103
Exercise Price	$0.15
Expiration Date	23-May-18
Warrants 7
Warrants	200,000
Exercise Price	$0.50
Expiration Date	23-Apr-19
Warrants 8
Warrants	561,798
Exercise Price	$0.45
Expiration Date	22-May-19
Warrant 9
Warrants	184,211
Exercise Price	$0.38
Expiration Date	10-Sep-19
Warrant 10
Warrants	325,521
Exercise Price	$0.46
Expiration Date	27-Sep-19
Warrant 11
Warrants	8,392,707
Exercise Price	$0.23
Expiration Date	2-Dec-19
Warrants 12
Warrants	$755,344
Exercise Price	$0.28
Expiration Date	2-Dec-19

4_STOCKHOLDERS_EQUITY_Details_3

4. STOCKHOLDERS' EQUITY (Details Narrative) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Stockholders Equity Details Narrative
Par value	$0.00	$0.00
Authorized preferred stock	3	3
Preferred stock par value	$0.00	$0.00
Shares Available under the plan	6,314,824	6,724,027
Share of common stock issued	96,889	70,479

5_Income_Taxes_Details

5. Income Taxes (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Deferred tax assets:
Net operating loss carryforwards	$466	$287
Deferred tax liabilities:
Intangible assets and other	25,994	22,737
Gross	26,460	23,025
Valuation allowance	-26,460	-23,025
Net	$0	$0

5_Income_taxes_Details_1

5. Income taxes (Details 1)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Income Tax Disclosure [Abstract]
Statutory federal tax rate	34.00%	34.00%
State taxes, net of federal benefit	400.00%	400.00%
Nondeductible expenses	0.00%	0.00%
Valuation allowance	-3800.00%	-3800.00%
Effective rate	0.00%	0.00%

5_Income_Taxes_Details_Narrati

5. Income Taxes (Details Narrative) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Income Taxes Details Narrative
NOL carryforwards		$68,400,000
NOL carryforwards available through	2034

6_Commitments_and_Contingencie2

6. Commitments and Contingencies (Details) (USD $)	Dec. 31, 2014
In Thousands, unless otherwise specified
Commitments and Contingencies Disclosure [Abstract]
2015	$211
2016	201
2017	98
Total	$510

10_Valuation_and_Qualifying_Ac2

10. Valuation and Qualifying Accounts (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Valuation and Qualifying Accounts [Abstract]
Beginning balance	$18	$12
Additions / (Adjustments)	58	6
Balance	$76	$18

10_Valuation_and_Qualifying_Ac3

10. Valuation and Qualifying Accounts (Details 1) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Valuation and Qualifying Accounts [Abstract]
Beginning balance	$184	$52
Additions / (Adjustments)	-40	132
Balance	$144	$184